| payload |
{"created_at":"2026-04-14T02:04:49.876 {"created_at":"2026-04-14T02:04:49.876253+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:dbe26f2bbfe2077d","evidence_event_ids":["evt_88e457e71482"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1863127/0001628280-26-024915.txt","as_of":"2026-04-14T02:04:49.876253+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1863127/0001628280-26-024915.txt","company":"Tyra Biosciences, Inc.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1863127/0001628280-26-024915.txt","article_chars":1584,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_2d8e4dff2a9281c2","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1863127/0001628280-26-024915.txt","content_type":"text/plain","enriched_at":"2026-04-14T02:18:27.067284+00:00","extraction_method":"trafilatura","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1863127/0001628280-26-024915.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1863127/0001628280-26-024915.txt","source_event_id":"evt_88e457e71482","source_quality":"medium","status_code":200,"version":"signal_enrichment_v2"},"form_type":"144","fp":"9135306f8a67e0d9","kind":"sec_filing","published_at":"20260413","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.62,"dates_mentioned":["2026-04-13","2026-04-14","2026-08-28","2018-08-28","2026-02-12","2026-03-12","2024-11-05"],"entities":[{"asset_class":"equity","name":"Tyra Biosciences, Inc.","relevance":"high","symbol":"","type":"issuer"},{"asset_class":"equity","name":"Daniel Bensen","relevance":"high","symbol":"","type":"reporting_owner"},{"asset_class":"other","name":"Merrill Lynch","relevance":"medium","symbol":"","type":"broker"}],"event_type":"listing","information_gaps":["The cleaned text does not clearly show the full Form 144 table fields (e.g., whether the listed quantities correspond to sale amounts, remaining shares, or other columns).","The security class is shown as \u201cCommon,\u201d but the ticker symbol is not explicitly provided in the extracted text.","No explicit sale price, aggregate amount, or broker execution details are visible in the provided text beyond the broker name reference.","The signal is labeled as a \u201cdelta,\u201d but no prior known state or comparison baseline is included in the prompt, so the exact change vs prior filings cannot be determined from the provided content alone."],"key_facts":["SEC accession number: 0001628280-26-024915.","Conformed submission type: Form 144.","Filed as of date: 2026-04-13 (date as of change: 2026-04-13).","Subject company/issuer: Tyra Biosciences, Inc. (CIK 0001863127).","Reporting owner: Daniel Bensen (CIK 0001880946), listed as an officer.","Form 144 includes common stock transactions with multiple entries showing quantities and dates (e.g., 8000 shares with dates 08/28/2018, 02/12/2026, 03/12/2026, and 04/13/2026 appear in the text).","The filing references Nasdaq and \u201cCommon\u201d in the security description lines.","Business address shown for the issuer and reporting owner: 2656 State Street, Carlsbad, CA 92008."],"numeric_claims":[{"label":"Form 144 filed date (as of)","value":"2026-04-13"},{"label":"Number of public documents","value":"1"},{"label":"Issuer CIK","value":"0001863127"},{"label":"Reporting owner CIK","value":"0001880946"},{"label":"Common shares quantity shown (example lot)","value":"8000"},{"label":"Common shares quantity shown (example lot)","value":"285000"},{"label":"Common shares quantity shown (example lot)","value":"262000"},{"label":"Common shares quantity shown (example lot)","value":"181000"}],"primary_claim":"On 2026-04-13, Tyra Biosciences, Inc. filed SEC Form 144 (accession 0001628280-26-024915) reporting Daniel Bensen as an officer/common stock holder with common shares covered for sale in specified quantities and dates.","relevance_score":0.45,"sentiment":"neutral","source_quality":"medium","summary":"Tyra Biosciences, Inc. filed a Form 144 on 2026-04-13. The filing lists Daniel Bensen as a reporting owner and includes planned/covered sales of common stock in multiple lots with specified dates.","topics":["SEC Form 144","insider/affiliate sale notice","common stock","Tyra Biosciences","Carlsbad CA"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 144 \u00b7 Tyra Biosciences, Inc. \u00b7 Filed 20260413","ticker":"TYRA","tickers":["TYRA"],"title":"TYRA filed 144","url":"https://www.sec.gov/Archives/edgar/data/1863127/0001628280-26-024915.txt"}}... |